Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, September 20, 2008

COPAXONE(R) Demonstrated Protective Effect in Patients with Clinically Isolated Syndrome Suggestive of Multiple Sclerosis

centredaily.com

Friday, Sep. 19, 2008
COPAXONE(R) Demonstrated Protective Effect in Patients with Clinically Isolated Syndrome Suggestive of Multiple Sclerosis

PreCISe Data Presented at World Congress on Treatment and Research in Multiple Sclerosis
JERUSALEM — New data from PreCISe, in clinically isolated syndrome patients, have demonstrated that COPAXONE(R) (glatiramer acetate injection) significantly improved neuro-axonal integrity in patients presenting with a first clinical event suggestive of multiple sclerosis (MS) versus patients who received placebo (p=0.03), as measured by proton magnetic resonance spectroscopy (MRS). This effect was maintained over two years of treatment.

The data represent the first evidence of neuro-axonal protection by a disease modifying therapy in patients presenting with a first clinical event suggestive of MS.

Data were derived from an ancillary study from the Phase III, randomized, placebo-controlled PreCISe trial, which demonstrated that patients treated with COPAXONE(R) (n=243) had a 45 percent reduction in the risk of developing clinically definite multiple sclerosis (CDMS) compared to those on the placebo (n=238).

"These newly announced data, so far shown in RRMS patients treated with COPAXONE(R), provide more evidence that treatment may control the neuronal damage associated with MS disease pathology," said Douglas Arnold, M.D., Professor of Neurology, McGill University and the primary investigator of this ancillary study. "The PreCISe trial demonstrated a significant benefit of COPAXONE(R) on both clinical and MRI disease activity, along with further reinforcing the excellent safety profile."

The data were presented along with two other presentations from the PreCISe study at the World Congress on Treatment and Research in Multiple Sclerosis, in Montreal, Canada. Additional data derived from the PreCISe study demonstrated that COPAXONE(R) significantly delayed time to conversion to CDMS and reduced magnetic resonance imaging (MRI) disease activity. The effect was robust among the PreCISe study population (n=481), as a whole and also in subgroups of patients (segmented by gender, age, type of unifocal manifestation as well as steroid treatment for the initial attack, and MRI findings at study baseline). Based on these data, applications for marketing authorization for the extension of its indication to include the treatment of patients with a first clinical event suggestive of MS were submitted in Europe and in the U.S. and are currently under review.

» Read More


Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

WORLD CONGRESS ON TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS

information obtained from the National MS Society

WORLD CONGRESS ON TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS
SEPTEMBER 17-20, 2008
PALAIS DES CONGRES DE MONTREAL
MONTREAL, QUEBEC, CANADA
www.msmontreal.org


SELECT HIGHLIGHTS from Friday September 19th and Saturday September 20th


Topics found below Include:
Treatment Challenges, Insights and Breakthroughs;
Reports on Emerging Therapies, Current Therapies, Possible MS Risk Factors;
More About MS in Children;
Progress Identifying Disease Predictors;
World Congress on MS: Late-Breaking News and Rehabilitation Strategies;
and More


Read to learn what was discussed at this MS event in Montreal on Friday and Saturday:

» Read More

Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

Friday, September 19, 2008

MS Learn Online! - October 2, 2008 - Managing Your Symptoms: Fatigue, Numbness, Dizziness, and Vertigo

October 2
Managing Your Symptoms: Fatigue, Numbness, Dizziness, and Vertigo
Introducing the all new

MS Learn Online!

As MS Learn Online enters its 10th year of webcasting educational programs to people with MS, we are excited to present our ALL NEW PLAYER.
The webcasts will be streamed in an engaging all-video format. The screen has two sizes, both larger than what was available on our previous player, and viewers will be able to easily navigate between webcasts without having to leave the player.
The new player will feature three channels or streams of programming:
  • Feature Presentation - Ten to 12-minute long webcasts on a certain topic. A new webcast or series of webcasts will debut the first and third Thursday of each month.
  • Daily Minute - A new one-minute nugget of information on MS for each day of the week.
  • Q&A - Once a week, a viewer's question will be answered by our MS Learn Online experts.

Did you see? Past MS Learn Online webcasts (audio/PowerPoint) are still available by going to www.nationalmssociety.org/mslearnonline.

If you have a pop-up blocker, you will need to disable it prior to participating in a MS Learn Online webcast.
Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity


Last update: 4:11 p.m. EDT Sept. 18, 2008

LUND, SWEDEN, Sep 18, 2008 (MARKET WIRE via COMTEX) -- New Crossover Data Presented at the World Congress on Treatment and Research in Multiple Sclerosis Shows Significant Reduction of
Gadolinium-Enhancing Lesions -

Jerusalem, Israel and Lund, Sweden, September 18, 2008 - New data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis (RRMS) demonstrated a significant reduction in the mean number of gadolinium-enhancing (GdE) lesions in both patients who switched from placebo to laquinimod and patients who continued with their initial laquinimod dose.

» Read More


============================================

Thursday, September 18, 2008

Biogen Idec Testing Regenerative Medicine Drug to Reverse the Path of Multiple Sclerosis

Contributed by Trent S in Miami

xconomy.com

Biogen Idec Testing Regenerative Medicine Drug to Reverse the Path of Multiple Sclerosis
Luke Timmerman 8/27/08

Biogen Idec has made a lot of its money on Avonex and Tysabri, drugs that slow down the rate of flare-ups for people with multiple sclerosis. Now the Cambridge, MA-based biotech company (NASDAQ: BIIB) is pursuing a loftier goal. It is working on the first experimental drug that may reverse the symptoms of the neurodegenerative disease.

The drug, being tested in animals and prepped for its first human trial, is designed to block a protein called Lingo-1 that interferes with body’s production of myelin, the fatty protective coating around nerve fibers.

» Read More

Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

Wednesday, September 17, 2008

Multiple sclerosis study confirms prevalence of the disease in Canada

MONTREAL — Canada has one of the highest rates of multiple sclerosis in the world and the country fails in providing adequate services for sufferers, a new study suggests.

The global survey by the World Health Organization and the Multiple Sclerosis International Federation focuses on the prevalence of the disease in more than 100 countries representing almost 88 per cent of the world's population.

The Atlas of Multiple Sclerosis was launched on Wednesday at the beginning of a four-day conference on the disease.

The study said MS strikes 133 people out of every 100,000 in Canada, the fifth-highest rate among the nations surveyed between 2004 and 2007.

Only in the United States, Germany, Norway and Hungary was the disease more prevalent.

Allan Thompson, a top official with the MS International Federation, says Canada has always been a model in terms of the treatment of MS and in addressing quality of life for sufferers.

"But I think even in Canada the services could be better," Thompson said in an interview, noting that support for employment is a big issue for Canadians with MS.

"Staying in employment is so important for quality of life and self-esteem and we just simply ignore it in most countries and Canada would probably fall into that group as well."

Stewart Wong, a spokesman for the Multiple Sclerosis Society of Canada, agreed.

"You can't easily earn income without reducing the benefits that are given to you by the government in a seamless way," he said.

"It means that in many cases people will choose not to work even if they are able to so they can afford their treatments and that's a very unfortunate thing."

Still, the study also highlights where Canada succeeds, Wong said.

"If someone has a first symptom of MS, they can go to a doctor, they can go to a neurologist, they can go to a support group and that's all within a couple of phone calls," he said.

"That stands out for us."

But Thompson believes the overall results highlight the lack of services, expertise and training in the area of MS worldwide.

"We're failing miserably and we're failing in even the most affluent countries," he said. "That's something that needs to be addressed urgently for which there's really no excuse."

Multiple sclerosis is a chronic disease that attacks the central nervous system, causing inflammation and damage. It has also been linked to environmental and genetic factors.

Wong said 2.5 million people worldwide have MS.

The MS Society of Canada says 55,000 Canadians have the disease.


Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

Worldwide survey seeks MS answers

Worldwide survey seeks MS answers
By Jill McGivering
BBC News

The number of people suffering from the neurological disease multiple sclerosis (MS) worldwide could be far more than the estimated 1.3m, researchers say.

A major new study into the disease has been launched by the Multiple Sclerosis International Federation (MSIF) and the World Health Organization (WHO).

They hope to answer key questions about MS, the cause of which is unclear.

Governments are being urged to invest more in education and services to improve sufferers' quality of life.

» Read More

Woman
Women are twice as likely as men to develop MS


Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.

============================================

Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R)

Yahoo Finance

Press Release Source: Merck Serono International S A

Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R)
in Patients at Risk of Developing Multiple Sclerosis


Wednesday September 17, 2:00 am ET


GENEVA, Switzerland, September 17 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment has been completed in the REFLEX trial (REbif FLEXible dosing in early multiple sclerosis). This randomized, double-blind, placebo-controlled, international Phase III trial is designed to evaluate the therapeutic benefit of Rebif® (interferon beta-1a) on the time to conversion to multiple sclerosis (MS) in people with a first clinical event suggestive of the disease.

» Read More

Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

Tuesday, September 16, 2008

Multiple Sclerosis Related : Tremors

The information found below comes directly for the NMSS Archives.

Many people with MS experience some degree of tremor, or uncontrollable shaking. It can occur in various parts of the body.

There are several types of tremor:

Intention tremor—generally is greatest during physical movement; there is no shaking when a person is at rest. The tremor develops and becomes more pronounced as the person tries to grasp or reach for something, or move a hand or foot to a precise spot. This is the most common and generally most disabling form of tremor that occurs in people with MS.

Postural tremor—generally is greatest when a limb or the whole body is being supported against gravity. For example, a person who has a postural tremor will shake while sitting or standing, but not while lying down.

Resting tremor—generally is greatest when the body part is at rest and is diminished with movement. More typical of Parkinson's disease than MS.

Nystagmus—produces jumpy eye movements.

Tremor occurs because there are plaques—damaged areas—along the complex nerve pathways that are responsible for coordination of movements. People with MS who have tremors may also have associated symptoms such as difficulty in speaking (dysarthria) or difficulty in swallowing (dysphagia)—activities that are governed by many of the same pathways involved in coordinating movement.

» Read More


Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

Multiple Sclerosis Symptoms

In multiple sclerosis, damage to the myelin in the central nervous system (CNS), and to the nerve fibers themselves, interferes with the transmission of nerve signals between the brain and spinal cord and other parts of the body. This disruption of nerve signals produces the primary symptoms of MS, which vary depending on where the damage has occurred.

Over the course of the disease, some symptoms will come and go, while others may be more lasting.

Read More On Multiple Sclerosis symptoms at Stu's News


Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

endMS Speeds Research Effort,

Multiple Sclerosis Society of Canada

Sep 16, 2008 10:22 ET

endMS Speeds Research Effort, Pushes to Cure Multiple Sclerosis

$60 million campaign funds national research and training network and enables Canadian scientists to accelerate pace of discovery

From left to right, Daniel Larouche, Yves Savoie and Dr. Jack Antel put together the last pieces of the puzzle symbolizing the launch of the endMS campaign in Montreal, Quebec, Tuesday, September 16, 2008. MARKETWIRE PHOTO/Multiple Sclerosis Society of Canada

TORONTO, ONTARIO--(Marketwire - Sept. 16, 2008) -

Editors Note: A photo for this release will be available via Marketwire on the picture wire of The Canadian Press.

Today, the Multiple Sclerosis Society of Canada announced the launch of endMS (www.endms.ca), a three-year national campaign with a goal of raising $60 million to fund research activities and establish the endMS Research and Training Network. The Network is a first in the MS community and represents an immediate, dedicated investment to advance Canada's leadership position in MS research.

"Collaboration is critical to significant, continued success in MS research," says Dr. Jack Antel director of the endMS Research and Training Network and clinical neurologist at McGill University. "When we work together, we can more clearly understand how our research findings apply to real patients and that sharing is what will continue to propel us forward toward a cure."

The goal of the endMS Research and Training Network is to accelerate research to end multiple sclerosis. The Network will help attract and train young researchers and retain seasoned scientists in an effort to speed the pace of discovery.

Canadian MS researchers are world-renowned and have made incredible advances in the knowledge and treatment of multiple sclerosis. However, if a limited number of young scientists make MS their professional focus, accelerated progress towards the end of MS could be in peril.

"With one of the highest rates of MS in the world, no known cure, and an annual economic impact that totals more than $1 billion annually, a lack of researchers is a vulnerability Canadians can ill afford," says Yves Savoie, president and CEO, Multiple Sclerosis Society of Canada.

"At the time I was diagnosed, I thought my life was over," says Jennifer Pevec, who was diagnosed with MS more than three years ago. "But today, research has given me new treatment options and a glimmer of hope. People in the prime of their lives don't just have to fade away with a diagnosis of MS. There is help and there is support."

About the endMS Research and Training Network

Through the endMS Campaign, the MS Society of Canada will create a research enterprise that will revolutionize the way the MS medical community communicates and collaborates. It will attract and retain the best and brightest minds by establishing Canada as the premier destination in the world in which to train for and pursue a career in MS research.

The goals of the endMS Research and Training Network include:

- Increase the pace of translation of research from the laboratory to the clinic so that effective therapies are available sooner.

- Foster active collaboration between clinicians and scientists through a technology-based infrastructure, including a comprehensive, online library of research data and educational material.

- Ensure that advancements in research benefit all people with MS regardless of community size or location.

"We are proud to lead an aggressive charge toward a cure for MS", says Savoie. "The endMS campaign continues our long-held tradition of research excellence. The funds raised will help ensure the Canadian research community maintains its world-class standing and will secure our place as the country of choice for MS researchers."

Canadian MS Research Successes

Historically, Canada has led the world in MS research. Canadian MS research successes include:

- The first North American pediatric MS clinic and the development of a comprehensive study looking at MS in children.

- Advancement of MRI technologies that allow for faster diagnosis and treatment of MS

- Pioneering work in bone marrow transplants and MS

- The world's largest genetic susceptibility study in MS

"When you look at the tremendous advances we've seen in MS in the last ten or twenty years, we know that we've already changed the face of the disease," says Dr. Antel. "And while those achievements are quite remarkable, they also represent a very real opportunity for our community, our teams, to build on the momentum and, together, move forward."

About the Multiple Sclerosis Society of Canada

The Multiple Sclerosis Society of Canada is the only national volunteer health agency in Canada that funds MS research, provides services for people with MS and family members and conducts public education programs. Since its founding in 1948, the MS Society has worked to hasten the discovery of the cause, effective treatment and cure for MS. From basic laboratory research to the development of new treatments for people with MS, the MS Society's research program is making a difference in people's lives today.

The MS Society also provides services to people who have multiple sclerosis and family members through its seven division offices and more than 120 chapters. MS Society volunteers and staff are also actively involved in educating health care professionals about MS and its treatment, in public awareness programs and in social action.

For more information, please contactMultiple Sclerosis Society of Canada
Stewart Wong
National Senior Manager, Media and Public Relations
(416) 967-3025
Email: stewart.wong@mssociety.ca
Website: www.endMS.ca

Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

Can Thinnest Needle can Make Injecting More Tolerable for Multiple Sclerosis Patients?

SOURCE: Bayer Health Care

Sep 15, 2008 09:39 ET

Betaseron® to Offer the Thinnest Needle in Multiple Sclerosis

View Press Release Videos

WAYNE, NJ--(MARKET WIRE)--Sep 15, 2008 -- Bayer HealthCare Pharmaceuticals Inc. today announced that Betaseron®* (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections.

"One of the barriers that many people with multiple sclerosis face in starting an MS treatment is injection anxiety," said Ludger Heeck, Vice President and General Manager, Specialty Medicine, Bayer HealthCare Pharmaceuticals Inc.

» Read More

Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

Teva to Present New treatment Data on Oral Laquinimod and ATL/TV1102 as well as Copaxone

Teva to Present New Treatment Data at World Congress for Multiple Sclerosis
Monday September 15, 8:01 am ET


JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. today announced presentations of several new studies at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal. New data will be presented on COPAXONE® (glatiramer acetate injection), a leading therapy for relapsing-remitting multiple sclerosis (RRMS) treatment, covering early treatment with COPAXONE®, long-term efficacy and safety.

» Read More

Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.
============================================

Monday, September 15, 2008

How scientists linked sunshine, diet and disease

From
September 14, 2008

The evidence that points unerringly to a link between vitamin D and Scotland's health statistics can be traced back to a journey undertaken in 1977 by two young Americans, Frank and Cedric Garland, who were studying cancer.

They regularly drove their white Ford Mustang from San Diego, California, to Johns Hopkins Medical School on the east coast, noticing the dramatic change in weather from sunshine to snow. When they saw a map showing that bowel cancer was much more common in the northeast of the United States than it is in the south and west, they immediately understood that sunshine might provide the explanation.

“Everyone else was thinking it must be something that people ate, like the amount of fibre or meat burnt on the barbecue,” said Frank Garland. “We were alert to the difference in climate because we had direct experience of it.”

READ COMPLETE Article from The Timesonline-Uk/Scotland by clicking link

Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.

============================================